Luka de Vos-Hillebrand and colleagues investigated the prognostic and predictive significance of CD52 mRNA expression in melanoma, examining its impact on prognosis, response to an immune checkpoint blockade (ICB), and elements of the tumor microenvironment (TME) [67]. The gene discussed is CD52; the disease is melanoma.